# A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

> **NCT01201902** · PHASE3 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 592 (actual)

## Conditions studied

- Influenza Infection

## Interventions

- **BIOLOGICAL:** Adjuvanted influenza A(H1N1) vaccine
- **BIOLOGICAL:** Adjuvanted influenza A(H1N1) vaccine
- **BIOLOGICAL:** un-adjuvanted influenza A(H1N1) vaccine
- **BIOLOGICAL:** Adjuvanted influenza A(H1N1) vaccine
- **BIOLOGICAL:** Adjuvanted influenza A(H1N1) vaccine

## Key facts

- **NCT ID:** NCT01201902
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2009-12
- **Final completion:** 2010-07
- **Target enrollment:** 592 (ACTUAL)
- **Last updated:** 2010-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01201902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01201902, "A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01201902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*